{
    "id": "dbpedia_2654_0",
    "rank": 92,
    "data": {
        "url": "https://www.thieme-connect.com/products/ejournals/html/10.1055/a-0903-2735",
        "read_more_link": "",
        "language": "en",
        "title": "Geburtshilfe und Frauenheilkunde / Full Text",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.thieme-connect.de/media/10.1055-s-00000020/10.1055-s-009-43778/cover_big.jpg          ",
            "https://www.thieme-connect.com/media/10.1055-s-00000000/btn-eRef-desktop.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-igf01.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-igf02.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_gg.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_oeggg.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_gs.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-igf01.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-igf02.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_gg.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_oeggg.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_gs.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-igfde01.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-igfde02.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_gg.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_oeggg.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png",
            "https://www.thieme-connect.de/media/gebfra/201908/thumbnails/10-1055-a-0903-2735-ilogo_gs.jpg",
            "https://www.thieme-connect.com/products/assets/desktop/css/img/icon-figure-zoom.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Medizinische Universität Wien",
            "Universitätsklinikum Schleswig-Holstein",
            "Campus Lübeck",
            "Universitätsklinikum Tübingen",
            "Universitätsspital Basel",
            "Ilm-Kreis-Kliniken",
            "Annahospital Herne",
            "Universitätsklinikum Heidelberg",
            "Marienhaus Klinikum Neuwied",
            "Asklepios Kliniken Hamburg"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "Thieme E-Books & E-Journals",
        "meta_lang": "en",
        "meta_favicon": "/products/assets/favicon-e6861aa09fc6a3a946cb99117c7bbb6d.png",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "Geburtshilfe Frauenheilkd 2019; 79(08): 813-833\n\nDOI: 10.1055/a-0903-2735\n\nGebFra Science\n\nGuideline/Leitlinie\n\nGeorg Thieme Verlag KG Stuttgart · New York\n\nPrevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) – Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes\n\nArticle in several languages: English | deutsch\n\nRichard Berger\n\n1 Frauenklinik, Marienhaus Klinikum Neuwied, Neuwied, Germany\n\n,\n\nHarald Abele\n\n2 Frauenklinik, Universitätsklinikum Tübingen, Tübingen, Germany\n\n,\n\nFranz Bahlmann\n\n3 Frauenklinik, Bürgerhospital Frankfurt, Frankfurt am Main, Germany\n\n,\n\nIvonne Bedei\n\n4 Frauenklinik, Klinikum Frankfurt Höchst, Frankfurt am Main, Germany\n\n,\n\nKlaus Doubek\n\n5 Frauenarztpraxis, Wiesbaden, Germany\n\n,\n\nUrsula Felderhoff-Müser\n\n6 Klinik für Kinderheilkunde I/Perinatalzentrum, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Germany\n\n,\n\nHerbert Fluhr\n\n7 Frauenklinik, Universitätsklinikum Heidelberg, Heidelberg, Germany\n\n,\n\nYves Garnier\n\n8 Frauenklinik, Klinikum Osnabrück, Osnabrück, Germany\n\n,\n\nSusanne Grylka-Baeschlin\n\n9 Zürcher Hochschule für angewandte Wissenschaften, Institut für Hebammen, Zürich, Switzerland\n\n,\n\nHanns Helmer\n\n10 Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien, Wien, Austria\n\n,\n\nEgbert Herting\n\n11 Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany\n\n,\n\nMarkus Hoopmann\n\n2 Frauenklinik, Universitätsklinikum Tübingen, Tübingen, Germany\n\n,\n\nIrene Hösli\n\n12 Frauenklinik, Universitätsspital Basel, Basel, Switzerland\n\n,\n\nUdo Hoyme\n\n13 Frauenklinik, Ilm-Kreis-Kliniken, Arnstadt, Germany\n\n,\n\nAlexandra Jendreizeck\n\n14 Bundesverband das frühgeborene Kind, Germany\n\n,\n\nHarald Krentel\n\n15 Frauenklinik, Annahospital Herne, Elisabethgruppe Katholische Kliniken Rhein Ruhr, Herne, Germany\n\n,\n\nRuben Kuon\n\n16 Frauenklinik, Universitätsklinikum Heidelberg, Heidelberg, Germany\n\n,\n\nWolf Lütje\n\n17 Frauenklinik, Evangelisches Amalie Sieveking-Krankenhaus Hamburg, Hamburg, Germany\n\n,\n\nSilke Mader\n\n18 European Foundation for the Care of the Newborn Infants\n\n,\n\nHolger Maul\n\n19 Frauenklinik, Asklepios Kliniken Hamburg, Hamburg, Germany\n\n,\n\nWerner Mendling\n\n20 Deutsches Zentrum für Infektionen in Gynäkologie und Geburtshilfe an der Frauenklinik, Helios Universitätsklinikum Wuppertal, Wuppertal, Germany\n\n,\n\nBarbara Mitschdörfer\n\n14 Bundesverband das frühgeborene Kind, Germany\n\n,\n\nTatjana Nicin\n\n21 Frauenklinik, Klinikum Hanau, Hanau, Germany\n\n,\n\nMonika Nothacker\n\n22 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Berlin, Germany\n\n,\n\nDirk Olbertz\n\n23 Abteilung Neonatologie und neonatologische Intensivmedizin, Klinikum Südstadt Rostock, Rostock, Germany\n\n,\n\nWerner Rath\n\n24 Emeritus, Universitätsklinikum Aachen, Aachen, Germany\n\n,\n\nClaudia Roll\n\n25 Vestische Kinder- und Jugendklinik Datteln, Universität Witten/Herdecke, Datteln, Germany\n\n,\n\nDietmar Schlembach\n\n26 Klinik für Geburtsmedizin, Klinikum Neukölln/Berlin Vivantes Netzwerk für Gesundheit, Berlin, Germany\n\n,\n\nEkkehard Schleußner\n\n27 Klinik für Geburtsmedizin, Universitätsklinikum Jena, Jena, Germany\n\n,\n\nFlorian Schütz\n\n16 Frauenklinik, Universitätsklinikum Heidelberg, Heidelberg, Germany\n\n,\n\nVanadin Seifert-Klauss\n\n28 Frauenklinik, Universitätsklinikum rechts der Isar München, München, Germany\n\n,\n\nSusanne Steppat\n\n29 Deutscher Hebammenverband, Germany\n\n,\n\nDaniel Surbek\n\n30 Universitäts-Frauenklinik, Inselspital, Universität Bern, Bern, Switzerland\n\n› Author Affiliations\n\nFurther Information\n\nCorrespondence/Korrespondenzadresse\n\nProf. Dr. med. Richard Berger\n\nMarienhaus Klinikum St. Elisabeth\n\nAkademisches Lehrkrankenhaus der Universitäten Mainz und Maastricht\n\nKlinik für Gynäkologie und Geburtshilfe\n\nFriedrich-Ebert-Straße 59\n\n56564 Neuwied\n\nGermany\n\nPublication History\n\nreceived 30 April 2019\n\naccepted 30 April 2019\n\nPublication Date:\n\n12 August 2019 (online)\n\nAbstract\n\nFull Text\n\nReferences\n\nFigures\n\nAbstract\n\nI Guideline Information\n\nGuidelines program\n\nCitation format\n\nGuideline documents\n\nGuideline authors (Table 1)\n\nII Guideline Application\n\nPurpose and objectives\n\nTargeted areas of patient care\n\nTarget user groups/target audience\n\nAdoption and period of validity\n\nIII Method\n\nBasic principle\n\nGrading of recommendations\n\nStatements\n\nAchieving consensus and strength of consensus\n\nExpert consensus\n\nAddendum of the OEGGG\n\nTo 6.9.1 Mode of delivery depending on fetal presentation and position\n\nTo 6.6.5 Application of antenatal steroids before late preterm delivery\n\nAddendum of the SGGG\n\nTo 6.6. Administration of antenatal steroids\n\nTo 1. Definition and Epidemiology (and various other chapters: 6.9.1., 6.9.6., 6.9.7., 8.8., 8.9.)\n\nTo 6.2. Tocolysis\n\nTo 8.8 Clinical management before GW 22\n\nIV Guideline\n\n6 Tertiary Prevention\n\n6.1 Bed rest\n\n6.2 Tocolysis\n\n6.2.1 Indications\n\n6.2.2 Drugs\n\n6.2.3 Combining several tocolytics\n\n6.2.4 Tocolysis for extremely preterm birth, multiple pregnancy and intrauterine growth restriction\n\n6.2.5 Long-term tocolysis\n\n6.3 Progesterone for maintenance tocolysis\n\n6.4 Cervical pessary for shortened cervical length after premature labor\n\n6.5 Administration of antibiotics for premature labor\n\n6.6 Administration of antenatal steroids\n\n6.6.1 Administration and dosage\n\n6.6.2 Starting in which week of gestation?\n\n6.6.3 Repeat administration of antenatal steroids\n\n6.6.4 Timing of antenatal steroid administration\n\n6.6.5 Administration of antenatal steroids and late preterm birth\n\n6.7 Emergency cerclage\n\n6.8 Neuroprotection\n\n6.8.1 Magnesium\n\n6.8.2 Delayed cord clamping\n\n6.9 Delivery\n\n6.9.1 Delivery depends on fetal presentation\n\n6.9.2 Longitudinal uterine incision for cesarean section\n\n6.9.3 Vaginal operative delivery\n\n6.9.4 Fetal blood gas analysis\n\n6.9.5 Antibiotic prophylaxis for group B streptococcus\n\n6.9.6 Cooperation with the Neonatology Department\n\n6.9.7 Terminal care\n\n7 Special Aspects Relating to Twin and Multiple Pregnancies\n\n7.1 Epidemiology and etiology\n\n7.2 Prevention\n\n7.2.1 Progesterone\n\n7.2.2 Cerclage\n\n7.2.3 Cervical pessary for shortened cervical length\n\n7.2.4 Cervical pessary after preterm labor and shortened cervical length\n\n7.2.5 Emergency cerclage\n\n8 Preterm Premature Rupture of Membranes (PPROM)\n\n8.1 Prevalence and Etiology\n\n8.2 Risk factors\n\n8.3 Diagnostic workup\n\n8.4 Latency period\n\n8.5 Maternal and fetal risks\n\n8.6 Triple I (Table 6)\n\n8.7 Maternal and fetal risks associated with Triple I\n\n8.8 Clinical management of PPROM before GW 22\n\n8.9 Clinical management of PPROM between (GW 22 + 0) GW 24 + 0 and GW 33 + 6\n\n8.9.1 Expectant management\n\n8.9.2 Administration of antenatal steroids\n\n8.9.3 Administration of antibiotics\n\n8.9.4 Tocolysis\n\n8.9.5 Neuroprotection\n\n8.9.6 Maternal and fetal monitoring\n\n8.9.7 Amniotic infusion\n\n8.9.8 Antibiotic prophylaxis for Group B streptococcus\n\n8.9.9 Delivery\n\n8.10 Clinical Management of PPROM between GW 34 + 0 and GW 36 + 6\n\n9 Psychosomatic Care and Supportive Therapy\n\nReferences/Literatur\n\nAbstract\n\nAims This is an official guideline of the German Society for Gynecology and Obstetrics (DGGG), the Austrian Society for Gynecology and Obstetrics (ÖGGG) and the Swiss Society for Gynecology and Obstetrics (SGGG). The aim of this guideline is to improve the prediction, prevention and management of preterm birth based on evidence obtained from recently published scientific literature, the experience of the members of the guideline commission and the views of self-help groups.\n\nMethods The members of the participating medical societies and organizations developed Recommendations and Statements based on the international literature. The Recommendations and Statements were adopted following a formal consensus process (structured consensus conference with neutral moderation, voting done in writing using the Delphi method to achieve consensus).\n\nRecommendations Part 2 of this short version of the guideline presents Statements and Recommendations on the tertiary prevention of preterm birth and the management of preterm premature rupture of membranes.\n\n#\n\nKey words\n\npreterm birth - preterm labor - cervical insufficiency - preterm premature rupture of membranes\n\nI Guideline Information\n\nGuidelines program\n\nFor information on the guidelines program, please refer to the end of the guideline.\n\n#\n\nCitation format\n\nPrevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) – Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes. Geburtsh Frauenheilk 2019; 79: 813–833\n\n#\n\nGuideline documents\n\nThe complete long version, a slide version of this guideline, a list of the conflicts of interest of all authors, and a guideline report on the methodological approach used, including the management of conflicts of interest, are available in German on the homepage of the AWMF: http://www.awmf.org/leitlinien/detail/ll/015-025.html\n\n#\n\nGuideline authors ([Table 1])\n\nTable 1 The following medical societies/working groups/organizations/associations were interested in participating in the compilation of the text of the guideline and in the consensus conference, and they nominated representatives to attend the consensus conference.\n\nAuthor\n\nMandate holder\n\nDGGG working group (AG)/AWMF/non-AWMF medical society/organization/association\n\n#\n\n#\n\nAbbreviations\n\nAFP: alpha-fetoprotein\n\nAUC: area under the curve\n\nCI: confidence interval\n\nCOX: cyclooxygenase\n\nCPAP: continuous positive airway pressure\n\nCRP: C-reactive protein\n\nCTG: cardiotocography\n\nfFN: fetal fibronectin\n\nFIRS: fetal inflammatory response syndrome\n\nGBS: group B streptococcus\n\nGW: week of gestation\n\nIGFBP-1: insulin-like growth factor-binding protein-1\n\nIL-6: interleukin-6\n\nNEC: necrotizing enterocolitis\n\nNICU: neonatal intensive care unit\n\nNNH: number needed to harm\n\nNNT: number needed to treat\n\nOR: odds ratio\n\n17-OHPC: 17α-hydroxyprogesterone caproate\n\nPAMG-1: placental alpha microgobulin-1\n\nphIGFBP-1: phosphorylated insulin-like growth factor-binding protein-1\n\nPIVH: periventricular/intraventricular hemorrhage\n\nPPROM: preterm premature rupture of membranes\n\nPVL: periventricular leukomalacia\n\nRDS: respiratory distress syndrome\n\nRR: relative risk\n\ns/p: status post\n\nTCO: total cervical occlusion\n\nTNF-α: tumor necrosis factor alpha\n\nTriple I: intrauterine inflammation or infection or both\n\nII Guideline Application\n\nPurpose and objectives\n\nThis guideline aims to improve both the outpatient and the inpatient care of patients at imminent risk of preterm birth in order to reduce the rate of preterm births. If preterm birth cannot be prevented, the aim is to reduce perinatal and neonatal morbidity and mortality. This should lead to improvements in the psychomotor and cognitive development of children born preterm.\n\n#\n\nTargeted areas of patient care\n\nOutpatient and/or inpatient care\n\n#\n\nTarget user groups/target audience\n\nThe recommendations of this guideline are aimed at gynecologists in private practice, gynecologists in hospitals, pediatricians in hospitals, midwives in private practice and midwives in hospitals. Other target user groups include advocacy groups for affected women and children, nursing staff (obstetrics/postnatal care, pediatric intensive care), medical and scientific societies and professional associations, institutions for quality assurance (e.g. IQTIG), healthcare policy institutions and decision-makers at the federal and state level, funding agencies and payers.\n\n#\n\nAdoption and period of validity\n\nThe validity of this guideline was confirmed by the executive boards of the participating medical societies, working groups, organizations and associations as well as by the executive boards of the DGGG, the SGGG and the OEGGG and the DGGG/OEGGG/SGGG guidelines commission in February 2019 and was thus confirmed in its entirety. This guideline is valid from 1 February 2019 through to 31 January 2022. Because of the contents of this guideline, this period of validity is only an estimate. The guideline may need to be updated earlier in urgent cases. If the guideline continues to mirror current knowledge, its period of validity may also be extended.\n\n#\n\n#\n\nIII Method\n\nBasic principle\n\nThe method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and requirements for different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest (S3) class. The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was divided into two subclasses: a systematic evidence-based subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches. This guideline is classified as: S2k\n\n#\n\nGrading of recommendations\n\nGrading of evidence and grading of recommendations is not envisaged for S2k-level guidelines. The individual Statements and Recommendations are differentiated by syntax, not by symbols ([Table 2]).\n\nTable 2 Grading of recommendations.\n\nLevel of recommendation\n\nSyntax\n\nIn addition to the level of evidence, the above listed classification of “Recommendations” also takes account of the clinical relevance of the underlying studies and the various measures/factors which were not included in the grading of evidence, such as the choice of patient cohort, intention-to-treat or per-protocol outcome analyses, medical and ethical practice when dealing with patients, country-specific applicability, etc.\n\n#\n\nStatements\n\nScientific statements given in this guideline which do not consist of any direct recommendations for action but are simple statements of fact are referred to as “Statements”. It is not possible to provide any information about the grading of evidence for these Statements.\n\n#\n\nAchieving consensus and strength of consensus\n\nAs part of the structured process to achieve consensus (S2k/S3 level), authorized participants attending the session vote on draft Statements and Recommendations. This can lead to significant changes in the wording, etc. Finally, the extent of consensus is determined based on the number of participants ([Table 3]).\n\nTable 3 Grading of strength of consensus.\n\nSymbol\n\nStrength of consensus\n\nExtent of agreement in percent\n\n+++\n\nStrong consensus\n\n> 95% of participants agree\n\n++\n\nConsensus\n\n> 75 – 95% of participants agree\n\n+\n\nMajority agreement\n\n> 50 – 75% of participants agree\n\n−\n\nNo consensus\n\n< 51% of participants agree\n\n#\n\nExpert consensus\n\nAs the name already implies, this term refers to consensus decisions taken with regard to specific Recommendations/Statements made without a prior systematic search of the literature (S2k) or for which evidence is lacking (S2e/S3). The term “expert consensus” (EC) used here is synonymous with terms used in other guidelines such as “good clinical practice” (GCP) or “clinical consensus point” (CCP). The strength of the recommendation is graded as previously described in the chapter “Grading of recommendations”, i.e., purely semantically (“must”/“must not” or “should”/“should not” or “may”/“may not”) without the use of symbols.\n\n#\n\nAddendum of the OEGGG\n\nTo 6.9.1 Mode of delivery depending on fetal presentation and position\n\nThe Austrian Society of Gynecology and Obstetrics (OEGGG) is of the opinion that there is no clinical or scientific basis for the Recommendation that cesarean section should be the preferred mode of delivery based on an assumed lower risk of perinatal cerebral hemorrhage. The OEGGG is of the opinion that the mode of delivery of infants at the limit of viability (GW 22 + 0 bis 24 + 6) must be adapted to take the individual maternal and fetal clinical situation into account. For singletons at the limit of viability and in cephalic presentation, the OEGGG recommends an individualized management of delivery, which takes the maternal and fetal clinical situation into account and where the clinical decision process also includes the option of vaginal delivery as the mode of delivery [1].\n\n#\n\nTo 6.6.5 Application of antenatal steroids before late preterm delivery\n\nBased on the results of the ALPS trial [2] and the recommendations of the Society for Maternal Fetal Medicine (SMFM), the OEGGG is of the opinion that the administration of antenatal steroids in GW 34 + 0 to GW 36 + 6 may be considered, in accordance with the specifications of the SMFM.\n\n#\n\n#\n\nAddendum of the SGGG\n\nTo 6.6. Administration of antenatal steroids\n\nThe opinion of the SGGG on the issues in this chapter is presented in SGGG Expert Letter No. 56, which discusses the indications for glucocorticoid therapy to promote antenatal lung maturation and the appropriate doses when preterm birth is imminent (only available in German: “Glucocorticoidtherapie zur antenatalen Lungenreifung bei drohender Frühgeburt: Indikationen und Dosierung”). Reasoning: The evidence-based recommendations in Switzerland differ slightly from those given in this guideline, particularly with regard to the administration of antenatal glucocorticoids in gestational weeks 34 + 0 to 36 + 0 [3].\n\n#\n\nTo 1. Definition and Epidemiology (and various other chapters: 6.9.1., 6.9.6., 6.9.7., 8.8., 8.9.)\n\nAs regards care at the limits of viability, please refer to the recommendations for Switzerland which were developed together with neonatologists. Reasoning: The recommendations for Switzerland diverge in many points from the recommendations for Germany. They are currently being revised [4].\n\n#\n\nTo 6.2. Tocolysis\n\nWith regard to tocolytic drugs, the use of beta-mimetics for tocolysis has been approved in Switzerland and they can be used as the tocolytic drug of first choice; see also SGGG Expert Letter No. 41 on tocolysis for preterm labor (only available in German: “Tokolyse bei vorzeitiger Wehentätigkeit”). Reasoning: The recommendations for Switzerland differ in many points from the recommendations for Germany [5].\n\n#\n\nTo 8.8 Clinical management before GW 22\n\nThe option of terminating the pregnancy should be mentioned to patients with a poor prognosis. Reasoning: The option of terminating the pregnancy by inducing the birth in cases where there is a serious physical or psychological risk to the mother is not mentioned in the guideline, even though it is clinically important.\n\n#\n\n#\n\n#\n\nIV Guideline\n\n6 Tertiary Prevention\n\n6.1 Bed rest\n\nConsensus-based Statement 6.S21\n\nExpert consensus\n\nStrength of consensus ++\n\n[6], [7], [8], [9], [10]\n\n#\n\n6.2 Tocolysis\n\nConsensus-based Recommendation 6.E18\n\nExpert consensus\n\nStrength of consensus +++\n\n6.2.1 Indications\n\nConsensus-based Recommendation 6.E19\n\nExpert consensus\n\nStrength of consensus +++\n\nConsensus-based Statement 6.S22\n\nExpert consensus\n\nStrength of consensus +++\n\nConsensus-based Statement 6.S23\n\nExpert consensus\n\nStrength of consensus +++\n\n[11], [12]\n\n#\n\n6.2.2 Drugs\n\nConsensus-based Recommendation 6.E20\n\nExpert consensus\n\nStrength of consensus ++\n\nOf all the tocolytic drugs, beta sympathomimetics have the greatest rate of maternal (up to 80% cardiovascular) and fetal side effects as well as requiring the most monitoring [12]. There is also the additional problem of lung edema which occurs in around 1/350 applications [13]. They should therefore no longer be used for tocolysis [14].\n\nThe data on the use of magnesium sulfate as a tocolytic drug is controversial. Meta-analyses [11], [12] showed that magnesium sulfate was an effective tocolytic in terms of prolonging the pregnancy by 48 hours compared to placebo (OR 2.46; 95% CI: 1.58 – 4.94); however, this flies in the face of the results and statements of the 2014 Cochrane Review [15], which were generated using 37 studies with 3571 pregnant women. According to the Cochrane Review, magnesium sulfate was not more effective than placebo or even no therapy at prolonging pregnancy for more than 48 hours and does not reduce the rate of preterm births. However, the tocolytic efficacy of magnesium sulfate depends in the dose, which in turn has an impact on the incidence of maternal side effects. International guidelines no longer recommend using magnesium sulfate for tocolysis [16], [17], [18].\n\nConsensus-based Recommendation 6.E21\n\nExpert consensus\n\nStrength of consensus ++\n\n[11], [12]\n\n#\n\n6.2.3 Combining several tocolytics\n\nConsensus-based Recommendation 6.E22\n\nExpert consensus\n\nStrength of consensus +++\n\n[13], [19]\n\nConsensus-based Recommendation 6.E23\n\nExpert consensus\n\nStrength of consensus +++\n\n[20]\n\n#\n\n6.2.4 Tocolysis for extremely preterm birth, multiple pregnancy and intrauterine growth restriction\n\nConsensus-based Statement 6.S24\n\nExpert consensus\n\nStrength of consensus +++\n\n[21]\n\n#\n\n6.2.5 Long-term tocolysis\n\nConsensus-based Recommendation 6.E24\n\nExpert consensus\n\nStrength of consensus +++\n\n[22], [23], [24], [25]\n\n#\n\n#\n\n6.3 Progesterone for maintenance tocolysis\n\nConsensus-based Recommendation 6.E25\n\nExpert consensus\n\nStrength of consensus +++\n\nA meta-analysis carried out in 2017 which selectively included high-quality studies on this issue found that the use of progesterone for maintenance tocolysis did not significantly reduce the rate of preterm births before the 37th week of gestation (OR 1.23, 95% CI: 0.91 – 1.67) [26].\n\n#\n\n6.4 Cervical pessary for shortened cervical length after premature labor\n\nConsensus-based Statement 6.S25\n\nExpert consensus\n\nStrength of consensus +++\n\nPratcorona et al. recently published a prospective randomized study which included 357 patients between GW 24 + 0 and GW 33 + 6 [27]. If patients had a shortened cervical length (≤ 25 mm between GW 24 + 0 and GW 29 + 6; ≤ 15 mm between GW 30 + 0 and GW 33 + 6) 48 hours after being treated for premature labor, they were managed either by placing a cervical pessary or by standard protocol. The primary study outcome, in this case, the preterm birth rate before the 34th week of gestation, did not differ significantly between groups (10.7 vs. 13.7%; RR 0.78 [95% CI: 0.45 – 1.38]). However, the preterm birth rate before the 37th week of gestation was significantly lower after placement of a cervical pessary (14.7 vs. 25.1%; RR 0.58 [95% CI: 0.38 – 0.90]) as was the number of patients readmitted to hospital after previously being treated for premature labor (4.5 vs. 20.0%; RR 0.23 [95% CI: 0.11 – 0.47]). However, these results could not be confirmed in the APOSTEL VI trial [28].\n\n#\n\n6.5 Administration of antibiotics for premature labor\n\nConsensus-based Recommendation 6.E26\n\nExpert consensus\n\nStrength of consensus +++\n\nMeta-analyses found that the administration of antibiotics to cases with premature labor and no rupture of membranes had no effect on the duration of the pregnancy, the preterm birth rate, respiratory distress syndrome or neonatal sepsis [29], [30]. Given these findings, the potential risks of administering antibiotics when their administration is not indicated need to be discussed.\n\n#\n\n6.6 Administration of antenatal steroids\n\n6.6.1 Administration and dosage\n\nConsensus-based Recommendation 6.E27\n\nExpert consensus\n\nStrength of consensus +++\n\n[31]\n\n#\n\n6.6.2 Starting in which week of gestation?\n\nConsensus-based Recommendation 6.E28\n\nExpert consensus\n\nStrength of consensus +++\n\nA recently published meta-analysis found 8 non-randomized studies on this issue [32]. The impact on neonatal mortality and morbidity of a single dose of corticosteroids administered in the period GW 22 + 0 to GW 23 + 6 is shown in [Tables 4] and [5].\n\nTable 4 Effects of antenatal steroids on the outcome of infants between GW 22 + 0 and GW 22 + 6 [32].\n\nGW 22 + 0 – GW 22 + 6\n\nOR\n\n95% CI\n\nNeonatal mortality\n\n0.58\n\n0.38 – 0.89\n\nIntraventricular cerebral hemorrhage (grade III – IV) or periventricular leukomalacia\n\n1.03\n\n0.55 – 1.93\n\nChronic pulmonary disease\n\n1.19\n\n0.52 – 2.73\n\nNecrotizing enterocolitis (> stage II)\n\n0.59\n\n0.03 – 12.03\n\nTable 5 Effects of antenatal steroids on the outcome of infants between GW 23 + 0 and GW 23 + 6 [32].\n\nGW 23 + 0 – GW 23 + 6\n\nOR\n\n95% CI\n\nNeonatal mortality\n\n0.50\n\n0.42 – 0.58\n\nIntraventricular cerebral hemorrhage (grade III – IV) or periventricular leukomalacia\n\n0.75\n\n0.55 – 1.03\n\nChronic pulmonary disease\n\n0.94\n\n0.59 – 1.51\n\nNecrotizing enterocolitis (> stage II)\n\n0.93\n\n0.66 – 1.32\n\nWhile neonatal mortality was significantly reduced after a single dose of corticosteroids, it apparently had no effect on morbidity. Given the rapid recent progress in the field of neonatal intensive care, prospective randomized studies on this issue are urgently required.\n\n#\n\n6.6.3 Repeat administration of antenatal steroids\n\nConsensus-based Recommendation 6.E29\n\nExpert consensus\n\nStrength of consensus +++\n\nZephyrin and colleagues used a Markov model to investigate how to achieve the right balance between risks and benefits with repeat administration of antenatal steroids [33]. The improved neonatal outcomes after multiple glucocorticoid administrations were set against the risk of fetal growth restriction. After 29 + 0 weeks of gestation, a repeat administration of antenatal steroids was associated with increasing risks for the infant ([Fig. 1]). Any repeat administration of antenatal steroids should therefore be limited to cases with a very low gestational age (< GW 29 + 0).\n\n#\n\n6.6.4 Timing of antenatal steroid administration\n\nConsensus-based Statement 6.S26\n\nExpert consensus\n\nStrength of consensus +++\n\nThere are now a number of cohort studies which show that perinatal morbidity and mortality depend significantly on the timing of lung maturity [34], [35], [36]. An example of this is shown in [Fig. 2], which depicts the neonatal survival of infants born preterm at ≤ 26 weeks of gestation [36].\n\nConsensus-based Recommendation 6.E30\n\nExpert consensus\n\nStrength of consensus +++\n\n[37], [38]\n\nConsensus-based Recommendation 6.E31\n\nExpert consensus\n\nStrength of consensus +++\n\n[39]\n\n#\n\n6.6.5 Administration of antenatal steroids and late preterm birth\n\nConsensus-based Recommendation 6.E32\n\nExpert consensus\n\nStrength of consensus ++\n\nThe ALPS trial found a significant reduction in neonatal respiratory distress in children born in late preterm at GW 34 + 0 to GW 36 + 5, whose mothers were given 2 × 12 mg betamethasone IM antenatally [2]. The ASTECS trial, which studied pregnant women who underwent elective cesarean section at term, also reported a significant reduction in RDS in children born to mothers who received 2 × 12 mg betamethasone antenatally [40]. However, at a school assessment carried out by teachers 10 years later, it was found that significantly more children from the intervention group were in the lower performance quartile and fewer children were in the top performance quartile [41]. No follow-up examinations of the children in the ALPS trial have been carried out to date. Because of this, no antenatal corticoids should be administered to this group of patients for the time being.\n\n#\n\n#\n\n6.7 Emergency cerclage\n\nConsensus-based Recommendation 6.E33\n\nExpert consensus\n\nStrength of consensus +++\n\nConsensus-based Recommendation 6.E34\n\nExpert consensus\n\nStrength of consensus +++\n\nA meta-analysis published in 2015 (n = 772 women from 11 studies, n = 496 underwent emergency cerclage placement, n = 276 were managed expectantly) found a significant prolongation of pregnancy and reduction of perinatal mortality after placement of an emergency cerclage for cervical dilation (duration of pregnancy: plus 5.4 weeks, perinatal mortality reduced from 58.5% to 29.1%) [42]. The administration of indomethacin and cefazolin increased the percentage of women who did not give birth within the following 4 weeks (92.3 vs. 62.5%) [43].\n\n#\n\n6.8 Neuroprotection\n\nConsensus-based Statement 6.S27\n\nExpert consensus\n\nStrength of consensus +++\n\n[44]\n\n6.8.1 Magnesium\n\nConsensus-based Recommendation 6.E35\n\nExpert consensus\n\nStrength of consensus +++\n\n[45], [46]\n\nTreatment should be started with a bolus of 4 – 6 g administered over 30 min, followed by a maintenance dose of 1 – 2 g for 12 h. The aim is to double the magnesium levels in maternal serum. If the birth does not occur within 12 h, magnesium may be administered again later on when preterm birth is once again imminent.\n\n#\n\n6.8.2 Delayed cord clamping\n\nConsensus-based Recommendation 6.E36\n\nExpert consensus\n\nStrength of consensus +++\n\n[47], [48], [49]\n\n#\n\n#\n\n6.9 Delivery\n\n6.9.1 Delivery depends on fetal presentation\n\nConsensus-based Recommendation 6.E37\n\nExpert consensus\n\nStrength of consensus ++\n\n[50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]\n\nConsensus-based Recommendation 6.E38\n\nExpert consensus\n\nStrength of consensus ++\n\n[64]\n\n#\n\n6.9.2 Longitudinal uterine incision for cesarean section\n\nConsensus-based Recommendation 6.E39\n\nExpert consensus\n\nStrength of consensus +++\n\nConsensus-based Recommendation 6.E40\n\nExpert consensus\n\nStrength of consensus +++\n\n[65], [66]\n\n#\n\n6.9.3 Vaginal operative delivery\n\nConsensus-based Recommendation 6.E41\n\nExpert consensus\n\nStrength of consensus ++\n\n[67]\n\n#\n\n6.9.4 Fetal blood gas analysis\n\nConsensus-based Recommendation 6.E42\n\nExpert consensus\n\nStrength of consensus +++\n\n#\n\n6.9.5 Antibiotic prophylaxis for group B streptococcus\n\nConsensus-based Recommendation 6.E43\n\nExpert consensus\n\nStrength of consensus +++\n\n[68]\n\n#\n\n6.9.6 Cooperation with the Neonatology Department\n\nConsensus-based Recommendation 6.E44\n\nExpert consensus\n\nStrength of consensus ++\n\n[69], [70], [71]\n\nThe treating pediatrician must be given all information about the pregnant woman which may be important for the initial medical treatment and therapy of the preterm infant. Such information includes any medication taken, HBsAg status, blood group, CMV antibody status (up to the 32nd week of gestation), findings from any prenatal diagnostic workups, and results of microbiological screening of the pregnant woman at imminent risk of preterm birth for GBS, MRSA, MRGN as well as the results of any repeat screenings if pregnancy is prolonged.\n\nConsensus-based Recommendation 6.E45\n\nExpert consensus\n\nStrength of consensus ++\n\n[72]\n\n#\n\n6.9.7 Terminal care\n\nConsensus-based Recommendation 6.E46\n\nExpert consensus\n\nStrength of consensus +++\n\n[73], [74], [75]\n\n#\n\n#\n\n#\n\n7 Special Aspects Relating to Twin and Multiple Pregnancies\n\n7.1 Epidemiology and etiology\n\nConsensus-based Statement 7.S28\n\nExpert consensus\n\nStrength of consensus +++\n\n[76], [77]\n\n#\n\n7.2 Prevention\n\n7.2.1 Progesterone\n\nConsensus-based Recommendation 7.E47\n\nExpert consensus\n\nStrength of consensus +++\n\n[78], [79]\n\nConsensus-based Recommendation 7.E48\n\nExpert consensus\n\nStrength of consensus +++\n\nAn individual patient data meta-analysis (IPDMA) of six studies [79], [80], [81], [82], [83], [84] carried out by Romero et al. in 2017, which compared the application of vaginal progesterone with placebo or no treatment in 303 asymptomatic women with twin pregnancy and a cervical length of ≤ 25 mm in the second trimester, found a significant reduction in preterm births before the 33rd week of gestation (31.4 vs. 43.1%; RR 0.69 [95% CI: 0.51 – 0.93]) and improved neonatal outcomes (e.g., lower neonatal mortality rate [RR 0.53; 95% CI 0.35 – 0.81], lower incidence of respiratory distress syndrome [RR 0.70; 95% CI: 0.56 – 0.89], fewer neonates with a birthweight < 1500 g [RR 0.53; 95% CI: 0.35 – 0.80]) [85].\n\n#\n\n7.2.2 Cerclage\n\nConsensus-based Recommendation 7.E49\n\nExpert consensus\n\nStrength of consensus +++\n\nThe first meta-analysis of three prospective randomized studies found a significantly higher preterm birth rate before the 35th week of gestation for women carrying a twin pregnancy after placement of a primary or secondary cerclage (76 vs. 36%; RR 2.15, 95% CI: 1.15 – 4.01) [86], [87], [88], [89]. Another meta-analysis has since been carried out which additionally took individual patient data into account [90]. This meta-analysis found that placement of a cerclage had no negative effect on the preterm birth rate or perinatal morbidity, at least for patients with a short cervix, before the 24th week of gestation.\n\n#\n\n7.2.3 Cervical pessary for shortened cervical length\n\nConsensus-based Recommendation 7.E50\n\nExpert consensus\n\nStrength of consensus +++\n\nGiven the fact that prospective randomized studies have reported both positive [91], [92], [93] and negative [94], [95] data, the decision whether or not to carry out this procedure must be made on a case-by-case basis.\n\n#\n\n7.2.4 Cervical pessary after preterm labor and shortened cervical length\n\nConsensus-based Statement 7.S29\n\nExpert consensus\n\nStrength of consensus +++\n\nIn a prospective randomized study which included 132 women with twin pregnancy between GW 24 + 0 and GW 33 + 6 [96], patients who were found to have a shortened cervical length (≤ 20 mm between GW 24 + 0 and GW 29 + 6; ≤ 10 mm between GW 30 + 0 and GW 33 + 6) 48 h after treatment for preterm labor either underwent placement of a cervical pessary or received the usual standard care. The primary study outcome – i.e., the preterm rate before the 34th week of gestation – was significantly lower in the intervention goup (16.4 vs. 32.3%; RR 0.51 [95% CI: 0.27 – 0.97]) as was the number of readmitted patients after treatment for preterm labor (5.6 vs. 21.5%; RR 0.28 [95% CI: 0.10 – 0.80]). Moreover, placement of a cervical pessary significantly reduced the prevalence of necrotizing enterocolitis (0 vs. 4.6%) and of neonatal sepsis (0 vs. 6.2%).\n\n#\n\n7.2.5 Emergency cerclage\n\nConsensus-based Recommendation 7.E51\n\nExpert consensus\n\nStrength of consensus +++\n\nAs has already been established for women with singleton pregnancies, cohort studies have shown that a twin pregnancy can also be prolonged if an emergency cerclage is placed in women with an opened cervix before GW 24 + 0 [97], [98], [99], [100].\n\n#\n\n#\n\n#\n\n8 Preterm Premature Rupture of Membranes (PPROM)\n\n8.1 Prevalence and Etiology\n\nConsensus-based Statement 8.S30\n\nExpert consensus\n\nStrength of consensus +++\n\n[101]\n\n#\n\n8.2 Risk factors\n\nConsensus-based Statement 8.S31\n\nExpert consensus\n\nStrength of consensus +++\n\n[102], [103]\n\n#\n\n8.3 Diagnostic workup\n\nConsensus-based Recommendation 8.E52\n\nExpert consensus\n\nStrength of consensus +++\n\n[104], [105]\n\nConsensus-based Recommendation 8.E53\n\nExpert consensus\n\nStrength of consensus +++\n\nWhen examining patients with PPROM, a digital examination must be avoided where possible, because digital examinations increase the risk of ascending infection and significantly reduce the latency period to delivery [106], [107].\n\n#\n\n8.4 Latency period\n\nConsensus-based Statement 8.S32\n\nExpert consensus\n\nStrength of consensus +++\n\n[108], [109]\n\n#\n\n8.5 Maternal and fetal risks\n\nConsensus-based Statement 8.S33\n\nExpert consensus\n\nStrength of consensus +++\n\n[110], [111], [112], [113], [114], [115]\n\n#\n\n8.6 Triple I ([Table 6])\n\nConsensus-based Statement 8.S34\n\nExpert consensus\n\nStrength of consensus +++\n\nTable 6 Classification of maternal fever and Triple I*.\n\nDefinition\n\n#\n\n8.7 Maternal and fetal risks associated with Triple I\n\nConsensus-based Statement 8.S35\n\nExpert consensus\n\nStrength of consensus +++\n\n[117], [118], [119], [120], [121], [122]\n\nConsensus-based Statement 8.S36\n\nExpert consensus\n\nStrength of consensus +++\n\n[123], [124]\n\n#\n\n8.8 Clinical management of PPROM before GW 22\n\nConsensus-based Recommendation 8.E54\n\nExpert consensus\n\nStrength of consensus +++\n\n[125], [126], [127]\n\nConsensus-based Recommendation 8.E55\n\nExpert consensus\n\nStrength of consensus +++\n\nAs almost all studies on antibiotic therapy in cases with rupture of membranes only recruited patients after the 24 + 0 week of gestation, there are no reliable data on the administration of antibiotics before the fetus has achieved viability. But the risk that the patient may develop sepsis due to ascending infection suggests that antibiotic therapy is advisable [128]. The same regimen as the one described for PPROM between (GW 22 + 0) GW 24 + 0 and GW 33 + 6 GW can be used.\n\nConsensus-based Recommendation 8.E56\n\nExpert consensus\n\nStrength of consensus +++\n\n#\n\n8.9 Clinical management of PPROM between (GW 22 + 0) GW 24 + 0 and GW 33 + 6\n\nConsensus-based Recommendation 8.E57\n\nExpert consensus\n\nStrength of consensus +++\n\n8.9.1 Expectant management\n\nConsensus-based Recommendation 8.E58\n\nExpert consensus\n\nStrength of consensus ++\n\nIf PPROM occurs between GW 24 + 0 and GW 33 + 6 or between GW 22 + 0 and GW 23 + 6 if maximum therapy is requested, the risks of ascending infection must be weighed against the neonatal risks which can result from preterm birth ([Table 7]). An ascending infection with chorioamnionitis, preterm placental abruption, pathological CTG, or umbilical cord prolapse are indications for immediate delivery of the fetus. Otherwise expectant management is currently the international standard of care [129].\n\nTable 7 Planned delivery vs. expectant management of PPROM between the 24th and the 37th week of gestation.\n\nPlanned delivery vs. expectant management\n\nRR\n\n95% CI\n\n[130]\n\nNeonatal sepsis\n\n0.93\n\n0.66 – 1.30\n\nNeonatal infection (positive blood culture)\n\n1.24\n\n0.70 – 2.21\n\nRDS\n\n1.26\n\n1.05 – 1.53\n\nCesarean section\n\n1.26\n\n1.11 – 1.44\n\nPerinatal mortality\n\n1.76\n\n0.89 – 3.50\n\nIntrauterine fetal death\n\n0.45\n\n0.13 – 1.57\n\nNeonatal mortality\n\n2.55\n\n1.17 – 5.56\n\nMechanical ventilation required\n\n1.27\n\n1.02 – 1.58\n\nTransfer to neonatal intensive care unit\n\n1.16\n\n1.08 – 1.24\n\nChorioamnionitis\n\n0.50\n\n0.26 – 0.95\n\nEndomyometritis\n\n1.61\n\n1.00 – 2.59\n\nInduction of labor\n\n2.18\n\n2.01 – 2.36\n\n#\n\n8.9.2 Administration of antenatal steroids\n\nConsensus-based Recommendation 8.E59\n\nExpert consensus\n\nStrength of consensus +++\n\n#\n\n8.9.3 Administration of antibiotics\n\nConsensus-based Recommendation 8.E60\n\nExpert consensus\n\nStrength of consensus ++\n\n[131]\n\nConsensus-based Recommendation 8.E61\n\nExpert consensus\n\nStrength of consensus +++\n\n[108], [129], [131]\n\n#\n\n8.9.4 Tocolysis\n\nConsensus-based Statement 8.S37\n\nExpert consensus\n\nStrength of consensus +++\n\n[132]\n\n#\n\n8.9.5 Neuroprotection\n\nSee 6.8.1.\n\n#\n\n8.9.6 Maternal and fetal monitoring\n\nConsensus-based Recommendation 8.E62\n\nExpert consensus\n\nStrength of consensus +++\n\nPregnant women with preterm premature rupture of membranes should be routinely examined for signs of infection. In addition to the above-mentioned clinical parameters, such signs also include symptoms such as painful uterus, uterine contractions, maternal blood pressure and heart rate [116]. Blood count and CRP must additionally be monitored at least once a day. However, the benefit of daily laboratory tests is disputed [133]. Kunze et al. reported an AUC of just 0.66 for a combination of maternal fever, CRP and leukocytes to predict FIRS [134]. Musilova et al. reported a sensitivity of 47%, specificity of 96%, positive predictive value of 42% and negative predictive value of 96% for a CRP value of 17.5 mg/l in maternal serum to predict intraamniotic infection or inflammation [135].\n\nDaily CTG monitoring of patients with PPROM is standard clinical practice. But currently there is no fetal monitoring method which can reliably detect intrauterine inflammation or infection. Neither CTG nor the use of a biophysical profile (CTG plus fetal breathing movements and other fetal movements, fetal tone and amniotic fluid volume assessment) are suitable predictors for intrauterine infection (CTG: sensitivity 39%; biophysical profile: 25%) [115].\n\nRegular monitoring of amniotic fluid volumes is similarly of little benefit. While a reduction in amniotic fluid volume increases the risk of umbilical cord compression and demonstrably reduces the time to the start of labor, its predictive value for a negative outcome is low [136]. The use of Doppler sonography has no proven benefits for premature rupture of membranes [137].\n\nConsensus-based Statement 8.S38\n\nExpert consensus\n\nStrength of consensus ++\n\n[138]\n\nConsensus-based Statement 8.S39\n\nExpert consensus\n\nStrength of consensus +++\n\n[134], [139]\n\n#\n\n8.9.7 Amniotic infusion\n\nConsensus-based Statement 8.S40\n\nExpert consensus\n\nStrength of consensus +++\n\n[140]\n\n#\n\n8.9.8 Antibiotic prophylaxis for Group B streptococcus\n\nSee the recommendations on GBS prophylaxis.\n\n#\n\n8.9.9 Delivery\n\nConsensus-based Recommendation 8.E63\n\nExpert consensus\n\nStrength of consensus +++\n\n[129], [130]\n\nConsensus-based Recommendation 8.E64\n\nExpert consensus\n\nStrength of consensus +++\n\n#\n\n#\n\n8.10 Clinical Management of PPROM between GW 34 + 0 and GW 36 + 6\n\nConsensus-based Recommendation 6.E65\n\nExpert consensus\n\nStrength of consensus +++\n\nA total of 1839 women between GW 34 + 0 and GW 36 + 6 who had preterm premature rupture of membranes (PPROM) were recruited into the PPROMT trial between 2004 and 2013 [141]. Immediate induction of labor was compared with expectant management. In the study group, 21% of infants were born after the 37th week of gestation to women managed expectantly compared to only 3% in the control group. The prevalence of neonatal sepsis was the same for both groups, however respiratory distress syndrome (RDS) occurred significantly less often after expectant management. In this group, the birthweight of the children was also significantly higher and the stay in the neonatal intensive care unit or in hospital was shorter. However, as expected, uterine bleeding before or during birth occurred more often in the mothers of these children as did peripartum fever. The c-section rate was significantly lower compared to the group who had induction of labor [141].\n\nThe results of the PPROMT trial were supported by the findings of the PPROMEXIL and PPROMEXIL-2 trials [142], [143]. But if Group B streptococcus colonization was diagnosed, the prevalence of early onset sepsis was significantly higher among affected neonates (15.2 vs. 1.8%; p = 0.04) [144].\n\nAccording to a meta-analysis of this issue which included 12 studies, expectant management was still not found to be associated with an increased prevalence of neonatal sepsis. Following immediate induction of labor, the rates for RDS, neonatal mortality, required ventilation, endomyometritis and cesarean section were significantly higher while the incidence of chorioamnionitis was lower [130]. A patient-level meta-analysis came to similar conclusions [145].\n\nConsensus-based Recommendation 8.E66\n\nExpert consensus\n\nStrength of consensus +++\n\n#\n\n#\n\n9 Psychosomatic Care and Supportive Therapy\n\nConsensus-based Recommendation 9.E67\n\nExpert consensus\n\nStrength of consensus ++\n\nIn addition to worries about the health consequences of a preterm birth (which are difficult to estimate), therapeutic measures, which can include immobilization, medication to stop contractions and the administration of corticosteroids, may be experienced as stressful. If there are additional stresses (a previous experience of loss, prior mental health problems, partnership difficulties, etc.), then the incidence of anxiety and depression is higher [146], [147], [148]. Particularly for large families, admission of the mother to hospital represents substantial organizational pressures for the family.\n\nThere are a number of psychometric tests which are used to detect psychological and social stress factors, such as HADS, the Babylotse Plus screening questionnaires, etc. [149].\n\nAffected couples should be offered acute psychological crisis intervention, followed by offers of supportive talks and psychotherapy where necessary. This also supports parent-child bonding.\n\nThe support offered by self-help groups such as the German federal association “Das Frühgeborene Kind” [The Preterm Infant] [150] can help affected parents, and parents should be informed about such options.\n\nAffected families should be actively offered options in the context of the Frühe Hilfe network. This is a German network that creates local and regional support systems offering coordinated services to parents and children, which aims to improve familial and social development opportunities for children and parents, both in the early stages and over the long term [151].\n\nThe “Babylotse” program, which arranges the transfer of families from the regular healthcare system to the Frühe Hilfe network and other social care systems has proven to be particularly useful. The core aspect of this program is the role it plays in guiding parents to find and use the most suitable options from among the numerous local choices available.\n\nAll of these measures are services which provide compassionate support to the patient and her family and which are offered in addition to the care provided by the attending midwife.\n\n#\n\n#\n\nGuideline Program\n\nEditors\n\nLeading Professional Medical Associations\n\nGerman Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. [DGGG])\n\nHead Office of DGGG and Professional Societies\n\nHausvogteiplatz 12, DE-10117 Berlin\n\ninfo@dggg.de\n\nhttp://www.dggg.de/\n\nPresident of DGGG\n\nProf. Dr. med. Anton Scharl\n\nDirektor der Frauenkliniken\n\nKlinikum St. Marien Amberg\n\nMariahilfbergweg 7, DE-92224 Amberg\n\nKliniken Nordoberpfalz AG\n\nSöllnerstraße 16, DE-92637 Weiden\n\nDGGG Guidelines Representatives\n\nProf. Dr. med. Matthias W. Beckmann\n\nUniversitätsklinikum Erlangen, Frauenklinik\n\nUniversitätsstraße 21 – 23, DE-91054 Erlangen\n\nProf. Dr. med. Erich-Franz Solomayer\n\nUniversitätsklinikum des Saarlandes\n\nGeburtshilfe und Reproduktionsmedizin\n\nKirrberger Straße, Gebäude 9, DE-66421 Homburg\n\nGuidelines Coordination\n\nDr. med. Paul Gaß, Dr. med. Gregor Olmes, Christina Meixner\n\nUniversitätsklinikum Erlangen, Frauenklinik\n\nUniversitätsstraße 21 – 23, DE-91054 Erlangen\n\nfk-dggg-leitlinien@uk-erlangen.de\n\nhttp://www.dggg.de/leitlinienstellungnahmen\n\nAustrian Society of Gynecology and Obstetrics (Österreichische Gesellschaft für Gynäkologie und Geburtshilfe [OEGGG])\n\nFrankgasse 8, AT-1090 Wien\n\nstephanie.leutgeb@oeggg.at\n\nhttp://www.oeggg.at\n\nPresident of OEGGG\n\nProf. Dr. med. Petra Kohlberger\n\nUniversitätsklinik für Frauenheilkunde Wien\n\nWähringer Gürtel 18–20, AT-1090 Wien\n\nOEGGG Guidelines Representatives\n\nProf. Dr. med. Karl Tamussino\n\nUniversitätsklinik für Frauenheilkunde und Geburtshilfe Graz\n\nAuenbruggerplatz 14, AT-8036 Graz\n\nProf. Dr. med. Hanns Helmer\n\nUniversitätsklinik für Frauenheilkunde Wien\n\nWähringer Gürtel 18–20, AT-1090 Wien\n\nSwiss Society of Gynecology and Obstetrics (Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [SGGG])\n\nGynécologie Suisse SGGG\n\nAltenbergstraße 29, Postfach 6, CH-3000 Bern 8\n\nsekretariat@sggg.ch\n\nhttp://www.sggg.ch/\n\nPresident in SGGG\n\nDr. med. Irène Dingeldein\n\nLängmatt 32, CH-3280 Murten\n\nSGGG Guidelines Representatives\n\nProf. Dr. med. Daniel Surbek\n\nUniversitätsklinik für Frauenheilkunde\n\nGeburtshilfe und feto-maternale Medizin\n\nInselspital Bern\n\nEffingerstraße 102, CH-3010 Bern\n\nProf. Dr. med. René Hornung\n\nKantonsspital St. Gallen, Frauenklinik\n\nRorschacher Straße 95, CH-9007 St. Gallen\n\n#\n\nConflict of Interest/Interessenkonflikt\n\nThe conflict of interest statements of all the authors are available in the long version of the guideline./Die Interessenkonflikterklärungen aller Autoren finden Sie in der Langversion der Leitlinie.\n\nReferences/Literatur\n\n1 Fischer T, Mörtl M, Reif P. et al. Statement by the OEGGG with Review of the Literature on the Mode of Delivery of Premature Infants at the Limit of Viability. Geburtsh Frauenheilk 2018; 78: 1212-1216\n\n2 Gyamfi-Bannerman C, Thom EA, Blackwell SC. et al. NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374: 1311-1320\n\n3 SGGG. Lungenreifungsinduktion bei drohender Frühgeburt. Online: https://www.sggg.ch/fileadmin/user_upload/56_Lungenreifungsinduktion_bei_drohender_Fruehgeburt.pdf last access: 28.04.2019\n\n4 Swiss-Paediatrics. Perinatale Betreuung an der Grenze der Lebensfähigkeit zwischen 22 und 26 vollendeten Schwangerschaftswochen. Online: http://www.swiss-paediatrics.org/sites/default/files/paediatrica/vol23/n1/pdf/10-12_0.pdf last access: 28.04.2019\n\n5 SGGG. Expertenbrief Tokolyse. Online: https://www.sggg.ch/fileadmin/user_upload/Dokumente/3_Fachinformationen/1_Expertenbriefe/De/41_Tokolyse_2013.pdf last access: 28.04.2019\n\n6 Sosa CG, Althabe F, Belizán JM. et al. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2015; (03) CD003581\n\n7 Hobel CJ, Ross MG, Bemis RL. et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol 1994; 170: 54-62\n\n8 Elliott JP, Miller HS, Coleman S. et al. A randomized multicenter study to determine the efficacy of activity restriction for preterm labor management in patients testing negative for fetal fibronectin. J Perinatol 2005; 25: 626-630\n\n9 Bigelow CA, Factor SH, Miller M. et al. Pilot Randomized Controlled Trial to Evaluate the Impact of Bed Rest on Maternal and Fetal Outcomes in Women with Preterm Premature Rupture of the Membranes. Am J Perinatol 2016; 33: 356-363\n\n10 da Silva Lopes K, Takemoto Y, Ota E. et al. Bed rest with and without hospitalisation in multiple pregnancy for improving perinatal outcomes. Cochrane Database Syst Rev 2017; (03) CD012031\n\n11 Haas DM, Imperiale TF, Kirkpatrick PR. et al. Tocolytic therapy: A meta-analysis and decision analysis. Obstet Gynecol 2009; 113: 585-594\n\n12 Haas DM, Caldwell DM, Kirkpatrick P. et al. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345: e6226\n\n13 de Heus R, Mol BW, Erwich JJ. et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009; 338: b744\n\n14 Vogel JP, Oladapo OT, Manu A. et al. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health 2015; 3: e589-e590\n\n15 Crowther CA, Brown J, McKinlay CJ. et al. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2014; (08) CD001060\n\n16 [Anonymous] Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol 2016; 128: e155-e164\n\n17 Sentilhes L, Senat MV, Ancel PY. et al. Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol 2017; 210: 217-224\n\n18 Di Renzo GC, Cabero Roura L, Facchinetti F. et al. Preterm Labor and Birth Management: Recommendations from the European Association of Perinatal Medicine. J Matern Fetal Neonatal Med 2017; 30: 2011-2030\n\n19 Vogel JP, Nardin JM, Dowswell T. et al. Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database Syst Rev 2014; (07) CD006169\n\n20 Martinez de Tejada B, Karolinski A, Ocampo MC. et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG 2015; 122: 80-91\n\n21 Miyazaki C, Moreno Garcia R, Ota E. et al. Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis. Reprod Health 2016; 13: 4\n\n22 Dodd JM, Crowther CA, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev 2012; (12) CD003927\n\n23 Naik Gaunekar N, Raman P, Bain E. et al. Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (10) CD004071\n\n24 van Vliet E, Dijkema GH, Schuit E. et al. Nifedipine maintenance tocolysis and perinatal outcome: an individual participant data meta-analysis. BJOG 2016; 123: 1753-1760\n\n25 Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (05) CD000940\n\n26 Wood S, Rabi Y, Tang S. et al. Progesterone in women with arrested premature labor, a report of a randomised clinical trial and updated meta-analysis. BMC Pregnancy Childbirth 2017; 17: 258\n\n27 Pratcorona L, Goya M, Merced C. et al. Cervical pessary to reduce preterm birth < 34 weeks of gestation after an episode of preterm labor and a short cervix: a randomized controlled trial. Am J Obstet Gynecol 2018; 219: 99.e16\n\n28 Hermans FJR, Schuit E, Bekker MN. et al. Cervical Pessary After Arrested Preterm Labor: A Randomized Controlled Trial. Obstet Gynecol 2018; 132: 741-749\n\n29 King J, Flenady V. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev 2002; (04) CD000246\n\n30 Simcox R, Sin WT, Seed PT. et al. Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis. Aust N Z J Obstet Gynaecol 2007; 47: 368-377\n\n31 Roberts D, Brown J, Medley N. et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; (03) CD004454\n\n32 Deshmukh M, Patole S. Antenatal corticosteroids for neonates born before 25 Weeks-A systematic review and meta-analysis. PLoS One 2017; 12: e0176090\n\n33 Zephyrin LC, Hong KN, Wapner RJ. et al. Gestational age-specific risks vs. benefits of multicourse antenatal corticosteroids for preterm labor. Am J Obstet Gynecol 2013; 209: 330.e337\n\n34 Norman M, Piedvache A, Borch K. et al. Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results from the EPICE Cohort. JAMA Pediatr 2017; 171: 678-686\n\n35 Liebowitz M, Clyman RI. Antenatal Betamethasone: A Prolonged Time Interval from Administration to Delivery Is Associated with an Increased Incidence of Severe Intraventricular Hemorrhage in Infants Born before 28 Weeks Gestation. J Pediatr 2016; 177: 114-120.e1\n\n36 Norberg H, Kowalski J, Marsal K. et al. Timing of antenatal corticosteroid administration and survival in extremely preterm infants: a national population-based cohort study. BJOG 2017; 124: 1567-1574\n\n37 van Baaren GJ, Vis JY, Wilms FF. et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014; 123: 1185-1192\n\n38 Melchor JC, Khalil A, Wing D. et al. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52: 442-451\n\n39 Khandelwal M, Chang E, Hansen C. et al. Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial. Am J Obstet Gynecol 2012; 206: 201.e1-201.e11\n\n40 Stutchfield P, Whitaker R, Russell I. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331: 662\n\n41 Stutchfield PR, Whitaker R, Gliddon AE. et al. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed 2013; 98: F195-F200\n\n42 Ehsanipoor RM, Seligman NS, Saccone G. et al. Physical Examination-Indicated Cerclage. Obstet Gynecol 2015; 126: 125-135\n\n43 Miller ES, Grobman WA, Fonseca L. et al. Indomethacin and antibiotics in examination-indicated cerclage: a randomized controlled trial. Obstet Gynecol 2014; 123: 1311-1316\n\n44 Volpe J. Neurology of the Newborn. Philadelphia: W.B. Saunders Company; 1995\n\n45 Doyle LW, Crowther CA, Middleton P. et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (01) CD004661\n\n46 Crowther CA, Middleton PF, Voysey M. et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med 2017; 14: e1002398\n\n47 Backes CH, Rivera BK, Haque U. et al. Placental transfusion strategies in very preterm neonates: A systematic review and meta-analysis. Obstet Gynecol 2014; 124: 47-56\n\n48 Tarnow-Mordi W, Morris J, Kirby A. et al. Delayed versus Immediate Cord Clamping in Preterm Infants. N Engl J Med 2017; 377: 2445-2455\n\n49 Fogarty M, Osborn DA, Askie L. et al. Delayed vs. early umbilical cord clamping for preterm infants: a systematic review and meta-analysis. Am J Obstet Gynecol 2018; 218: 1-18\n\n50 Jonas HA, Khalid N, Schwartz SM. The relationship between Caesarean section and neonatal mortality in very-low-birthweight infants born in Washington State, USA. Paediatr Perinat Epidemiol 1999; 13: 170-189\n\n51 Lee HC, Gould JB. Survival rates and mode of delivery for vertex preterm neonates according to small- or appropriate-for-gestational-age status. Pediatrics 2006; 118: e1844\n\n52 Muhuri PK, Macdorman MF, Menacker F. Method of delivery and neonatal mortality among very low birth weight infants in the United States. Matern Child Health J 2006; 10: 47-53\n\n53 Malloy MH. Impact of cesarean section on neonatal mortality rates among very preterm infants in the United States, 2000–2003. Pediatrics 2008; 122: 285-292\n\n54 Jonas HA, Lumley JM. The effect of mode of delivery on neonatal mortality in very low birthweight infants born in Victoria, Australia: Caesarean section is associated with increased survival in breech-presenting, but not vertex-presenting, infants. Paediatr Perinat Epidemiol 1997; 11: 181-199\n\n55 Riskin A, Riskin-Mashiah S, Lusky A. et al. The relationship between delivery mode and mortality in very low birthweight singleton vertex-presenting infants. BJOG 2004; 111: 1365-1371\n\n56 Wylie BJ, Davidson LL, Batra M. et al. Method of delivery and neonatal outcome in very low-birthweight vertex-presenting fetuses. Am J Obstet Gynecol 2008; 198: 4\n\n57 Ghi T, Maroni E, Arcangeli T. et al. Mode of delivery in the preterm gestation and maternal and neonatal outcome. J Matern Fetal Neonatal Med 2010; 23: 1424-1428\n\n58 Durie DE, Sciscione AC, Hoffman MK. et al. Mode of delivery and outcomes in very low-birth-weight infants in the vertex presentation. Am J Perinatol 2011; 28: 195-200\n\n59 Reddy UM, Zhang J, Sun L. et al. Neonatal mortality by attempted route of delivery in early preterm birth. Am J Obstet Gynecol 2012; 207: 117.e1-117.e8\n\n60 Barzilay E, Gadot Y, Koren G. Safety of vaginal delivery in very low birthweight vertex singletons: a meta-analysis. J Matern Fetal Neonatal Med 2016; 29: 3724-3729\n\n61 Humberg A, Hartel C, Paul P. et al. Delivery mode and intraventricular hemorrhage risk in very-low-birth-weight infants: Observational data of the German Neonatal Network. Eur J Obstet Gynecol Reprod Biol 2017; 212: 144-149\n\n62 Holzer I, Lehner R, Ristl R. et al. Effect of delivery mode on neonatal outcome among preterm infants: an observational study. Wien Klin Wochenschr 2017; 129: 612-617\n\n63 Racusin DA, Antony KM, Haase J. et al. Mode of Delivery in Premature Neonates: Does It Matter?. AJP Rep 2016; 6: e251-e259\n\n64 Bergenhenegouwen L, Vlemmix F, Ensing S. et al. Preterm breech presentation: A comparison of intended vaginal and intended cesarean delivery. Obstet Gynecol 2015; 126: 1223-1230\n\n65 Landon MB, Hauth JC, Leveno KJ. et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 2004; 351: 2581-2589\n\n66 Landon MB, Lynch CD. Optimal timing and mode of delivery after cesarean with previous classical incision or myomectomy: a review of the data. Semin Perinatol 2011; 35: 257-261\n\n67 Aberg K, Norman M, Ekeus C. Preterm birth by vacuum extraction and neonatal outcome: A population-based cohort study. BMC Pregnancy Childbirth 2014; 14: 42\n\n68 Franz A, Härtel C, Herting E, für die Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI) (Federführung); Kehl S für die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG); Gille C für die Deutsche Gesellschaft für pädiatrische Infektiologie (DGPI); Doubek K für den Berufsverband der Frauenärzte BVF e. V.; Spellerberg B für die Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM); Maier RF, Vetter K, für die Deutsche Gesellschaft für Perinatale Medizin (DGPM), Eglin K. für den Bundesverband „Das frühgeborene Kind“ e. V. (BVDfK). Sepsis bei Neugeborenen-frühe Form-durch Streptokokken der Gruppe B, Prophylaxe. Online: https://www.awmf.org/leitlinien/detail/ll/024-020.html last access: 03.12.2018\n\n69 Simon A, (Leiter der Arbeitsgruppe) Christoph J, Geffers C. et al. Empfehlung zur Prävention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1500 g. Online: https://www.rki.de/DE/Content/Infekt/Krankenhaushygiene/Kommission/Downloads/Neo_Rili.pdf?__blob=publicationFile last access: 28.04.2019\n\n70 Simon A. (federführender Autor) Ergänzende Empfehlung (2011) zur „Prävention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1.500 g“ (2007). Online: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2012/Ausgaben/02_12.pdf?__blob=publicationFile last access: 28.04.2019\n\n71 Christoph J, Dame C, Eckmanns T. et al. Praktische Umsetzung sowie krankenhaushygienische und infektionspräventive Konsequenzen des mikrobiellen Kolonisationsscreenings bei intensivmedizinisch behandelten Früh- und Neugeborenen. Online: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/42_13.pdf?__blob=publicationFile last access: 28.04.2019\n\n72 Richtlinie Qualitätssicherungs-Richtlinie Früh- und Reifgeborene, Stand: Inkrafttreten 01.01.2018 des Gemeinsamen Bundesausschusses über Maßnahmen zur Qualitätssicherung der Versorgung von Früh- und Reifgeborenen gemäß § 136 Absatz 1 Nummer 2 SGBV in Verbindung mit § 92 Abs. 1 Satz 2 Nr. 13 SGB V. Online: https://www.g-ba.de/downloads/62-492-1487/QFR-RL_2017-10-19_iK-2018-01-01.pdf last access: 28.04.2019\n\n73 Destatis. Todesursachen. Online: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Todesursachen.html last access: 28.04.2019\n\n74 Bundesverband „Das frühgeborene Kind“ e.V.. Leitsätze für Palliativversorgung und Trauerbegleitung in der Peri- und Neonatologie. Online: https://www.fruehgeborene.de/fuer-fachleute/palliativversorgung-und-trauerbegleitung last access: 28.04.2019\n\n75 Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung. Deutsches Ärzteblatt: Ausgabe A, Praxis-Ausgabe: niedergelassene Ärzte 2011; 108 (07) A346-A348 Online: https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/Sterbebegleitung_17022011.pdf last access: 28.04.2019\n\n76 IQTIG. Bundesauswertung zum Erfassungsjahr 2017 – Geburtshilfe Qualitätsindikatoren. Online: https://iqtig.org/downloads/auswertung/2017/16n1gebh/QSKH_16n1-GEBH_2017_BUAW_V02_2018-08-01.pdf last access: 28.04.2019\n\n77 AQUA-Institut. 16/1 – Geburtshilfe Qualitätsindikatoren. Online: https://sqg.de/downloads/Bundesauswertungen/2014/bu_Gesamt_16N1-GEBH_2014.pdf last access: 28.04.2019\n\n78 Dodd JM, Grivell RM, OBrien CM. et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev 2017; (10) CD012024\n\n79 Serra V, Perales A, Meseguer J. et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG 2013; 120: 50-57\n\n80 Fonseca EB, Celik E, Parra M. et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357: 462-469\n\n81 Cetingoz E, Cam C, Sakalli M. et al. Progesterone effects on preterm birth in high-risk pregnancies: A randomized placebo-controlled trial. Arch Gynecol Obstet 2011; 283: 423-429\n\n82 Brizot ML, Hernandez W, Liao AW. et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2015; 213: 82.e1-82.e9\n\n83 Elrefaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet 2016; 293: 61-67\n\n84 Rode L, Klein K, Nicolaides KH. et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011; 38: 272-280\n\n85 Romero R, Conde-Agudelo A, El-Refaie W. et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017; 49: 303-314\n\n86 Berghella V, Odibo AO, To MS. et al. Cerclage for short cervix on ultrasonography: Meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106: 181-189\n\n87 Rust OA, Atlas RO, Reed J. et al. Revisiting the short cervix detected by transvaginal ultrasound in the second trimester: why cerclage therapy may not help. Am J Obstet Gynecol 2001; 185: 1098-1105\n\n88 Berghella V, Odibo AO, Tolosa JE. Cerclage for prevention of preterm birth in women with a short cervix found on transvaginal ultrasound examination: a randomized trial. Am J Obstet Gynecol 2004; 191: 1311-1317\n\n89 Althuisius SM, Dekker GA, Hummel P. et al. Final results of the Cervical Incompetence Prevention Randomized Cerclage Trial (CIPRACT): therapeutic cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol 2001; 185: 1106-1112\n\n90 Saccone G, Rust O, Althuisius S. et al. Cerclage for short cervix in twin pregnancies: systematic review and meta-analysis of randomized trials using individual patient-level data. Acta Obstet Gynecol Scand 2015; 94: 352-358\n\n91 Liem S, Schuit E, Hegeman M. et al. Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label randomised controlled trial. Lancet 2013; 382: 1341-1349\n\n92 Goya M, de la Calle M, Pratcorona L. et al. PECEP-Twins Trial Group. Cervical pessary to prevent preterm birth in women with twin gestation and sonographic short cervix: A multicenter randomized controlled trial (PECEP-Twins). Am J Obstet Gynecol 2016; 214: 145-152\n\n93 Dang VQ, Nguyen LK, He YTN. et al. Cervical pessary versus vaginal progesterone for the prevention of preterm birth in women with a twin pregnancy and a cervix < 38 mm: A randomized controlled trial. Am J Obstet Gynecol 2018; 218: 603-604\n\n94 Nicolaides KH, Syngelaki A, Poon LC. et al. Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. Am J Obstet Gynecol 2016; 214: 3.e1-3.e9\n\n95 Berghella V, Dugoff L, Ludmir J. Prevention of preterm birth with pessary in twins (PoPPT): a randomized controlled trial. Ultrasound Obstet Gynecol 2017; 49: 567-572\n\n96 Carreras E. Cervical pessary for preventing birth in Twin pregnancies with maternal short cervix after an episode of threatened preterm labour: randomised control trial. Abstract, 17th World Congress in Fetal Medicine, Athen 2018.\n\n97 Rebarber A, Bender S, Silverstein M. et al. Outcomes of emergency or physical examination-indicated cerclage in twin pregnancies compared to singleton pregnancies. Eur J Obstet Gynecol Reprod Biol 2014; 173: 43-47\n\n98 Miller ES, Rajan PV, Grobman WA. Outcomes after physical examination-indicated cerclage in twin gestations. Am J Obstet Gynecol 2014; 211: 46.e1-46.e5\n\n99 Roman A, Rochelson B, Fox NS. et al. Efficacy of ultrasound-indicated cerclage in twin pregnancies. Am J Obstet Gynecol 2015; 212: 788.e1-788.e6\n\n100 Park JY, Cho SH, Jeon SJ. et al. Outcomes of physical examination-indicated cerclage in twin pregnancies with acute cervical insufficiency compared to singleton pregnancies. J Perinat Med 2018; 46: 845-852\n\n101 van der Heyden JL. Preterm prelabor rupture of membranes: different gestational ages, different problems [Thesis]. Maastricht: Maastricht University; 2014\n\n102 Mercer BM, Goldenberg RL, Moawad AH. et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181: 1216-1221\n\n103 Asrat T, Lewis DF, Garite TJ. et al. Rate of recurrence of preterm premature rupture of membranes in consecutive pregnancies. Am J Obstet Gynecol 1991; 165: 1111-1115\n\n104 Ramsauer B, Vidaeff AC, Hosli I. et al. The diagnosis of rupture of fetal membranes (ROM): a meta-analysis. J Perinat Med 2013; 41: 233-240\n\n105 Palacio M, Kuhnert M, Berger R. et al. Meta-analysis of studies on biochemical marker tests for the diagnosis of premature rupture of membranes: comparison of performance indexes. BMC Pregnancy Childbirth 2014; 14: 183\n\n106 Munson LA, Graham A, Koos BJ. et al. Is there a need for digital examination in patients with spontaneous rupture of the membranes?. Am J Obstet Gynecol 1985; 153: 562-563\n\n107 Alexander JM, Mercer BM, Miodovnik M. et al. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. Am J Obstet Gynecol 2000; 183: 1003-1007\n\n108 Mercer BM, Miodovnik M, Thurnau GR. et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997; 278: 989-995\n\n109 Melamed N, Hadar E, Ben-Haroush A. et al. Factors affecting the duration of the latency period in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2009; 22: 1051-1056\n\n110 Garite TJ, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol 1982; 59: 539-545\n\n111 Beydoun SN, Yasin SY. Premature rupture of the membranes before 28 weeks: Conservative management. Am J Obstet Gynecol 1986; 155: 471-479\n\n112 Major CA, de Veciana M, Lewis DF. et al. Preterm premature rupture of membranes and abruptio placentae: is there an association between these pregnancy complications?. Am J Obstet Gynecol 1995; 172 (2 Pt 1): 672-676\n\n113 Ananth CV, Oyelese Y, Srinivas N. et al. Preterm premature rupture of membranes, intrauterine infection, and oligohydramnios: Risk factors for placental abruption. Obstet Gynecol 2004; 104: 71-77\n\n114 Soraisham AS, Singhal N, McMillan DD. et al. A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. Am J Obstet Gynecol 2009; 200: 372.e1-372.e6\n\n115 Lewis DF, Robichaux AG, Jaekle RK. et al. Expectant management of preterm premature rupture of membranes and nonvertex presentation: what are the risks?. Am J Obstet Gynecol 2007; 196: 6\n\n116 Higgins RD, Saade G, Polin RA. et al. Evaluation and Management of Women and Newborns With a Maternal Diagnosis of Chorioamnionitis: Summary of a Workshop. Obstet Gynecol 2016; 127: 426-436\n\n117 Gibbs RS, Blanco JD, St Clair PJ. et al. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. J Infect Dis 1982; 145: 1-8\n\n118 Silver RK, Gibbs RS, Castillo M. Effect of amniotic fluid bacteria on the course of labor in nulliparous women at term. Obstet Gynecol 1986; 68: 587-592\n\n119 Blanco JD, Gibbs RS, Malherbe H. et al. A controlled study of genital mycoplasmas in amniotic fluid from patients with intra-amniotic infection. J Infect Dis 1983; 147: 650-653\n\n120 Gibbs RS, Blanco JD, St Clair PJ. et al. Mycoplasma hominis and intrauterine infection in late pregnancy. Sex Transm Dis 1983; 10: 303-306\n\n121 Gibbs RS, Blanco JD, Lipscomb K. et al. Asymptomatic parturient women with high-virulence bacteria in the amniotic fluid. Am J Obstet Gynecol 1985; 152 (6 Pt 1): 650-654\n\n122 Hauth JC, Gilstrap LC, Hankins GDV. et al. Term maternal and neonatal complications of acute chorioamnionitis. Obstet Gynecol 1985; 66: 59-62\n\n123 Gomez R, Romero R, Ghezzi F. et al. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998; 179: 194-202\n\n124 Hofer N, Kothari R, Morris N. et al. The fetal inflammatory response syndrome is a risk factor for morbidity in preterm neonates. Am J Obstet Gynecol 2013; 209: 542.e1-542.e11\n\n125 Waters TP, Mercer BM. The management of preterm premature rupture of the membranes near the limit of fetal viability. Am J Obstet Gynecol 2009; 201: 230-240\n\n126 van Teeffelen AS, van der Ham DP, Oei SG. et al. The accuracy of clinical parameters in the prediction of perinatal pulmonary hypoplasia secondary to midtrimester prelabour rupture of fetal membranes: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2010; 148: 3-12\n\n127 Blott M, Greenough A. Neonatal outcome after prolonged rupture of the membranes starting in the second trimester. Arch Dis Child 1988; 63: 1146-1150\n\n128 [Anonymous] Obstetric Care Consensus No. 6 Summary: Periviable Birth. Obstet Gynecol 2017; 130: 926-928\n\n129 [Anonymous] ACOG Practice Bulletin No. 188: Prelabor Rupture of Membranes. Obstet Gynecol 2018; 131: e14\n\n130 Bond DM, Middleton P, Levett KM. et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeksʼ gestation for improving pregnancy outcome. Cochrane Database Syst Rev 2017; (03) CD004735\n\n131 Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2013; (12) CD001058\n\n132 Mackeen AD, Seibel-Seamon J, Muhammad J. et al. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev 2014; (02) CD007062\n\n133 Tita AT, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol 2010; 37: 339-354\n\n134 Kunze M, Klar M, Morfeld CA. et al. Cytokines in noninvasively obtained amniotic fluid as predictors of fetal inflammatory response syndrome. Am J Obstet Gynecol 2016; 215: 96.e1-96.e98\n\n135 Musilova I, Kacerovsky M, Stepan M. et al. Maternal serum C-reactive protein concentration and intra-amniotic inflammation in women with preterm prelabor rupture of membranes. PLoS One 2017; 12: e0182731\n\n136 Mercer BM, Rabello YA, Thurnau GR. et al. The NICHD-MFMU antibiotic treatment of preterm PROM study: impact of initial amniotic fluid volume on pregnancy outcome. Am J Obstet Gynecol 2006; 194: 438-445\n\n137 Abramowicz JS, Sherer DM, Warsof SL. et al. Fetoplacental and uteroplacental Doppler blood flow velocity analysis in premature rupture of membranes. Am J Perinatol 1992; 9: 353-356\n\n138 Dudley J, Malcolm G, Ellwood D. Amniocentesis in the management of preterm premature rupture of the membranes. Aust N Z J Obstet Gynaecol 1991; 31: 331-336\n\n139 Musilova I, Bestvina T, Hudeckova M. et al. Vaginal fluid interleukin-6 concentrations as a point-of-care test is of value in women with preterm prelabor rupture of membranes. Am J Obstet Gynecol 2016; 215: 619.e1-619.e12\n\n140 Hofmeyr GJ, Eke AC, Lawrie TA. Amnioinfusion for third trimester preterm premature rupture of membranes. Cochrane Database Syst Rev 2014; (03) CD000942\n\n141 Morris JM, Roberts CL, Bowen JR. et al. Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. Lancet 2016; 387: 444-452\n\n142 van der Ham DP, Vijgen SM, Nijhuis JG. et al. Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks: a randomized controlled trial. PLoS Med 2012; 9: e1001208\n\n143 van der Ham DP, van der Heyden JL, Opmeer BC. et al. Management of late-preterm premature rupture of membranes: the PPROMEXIL-2 trial. Am J Obstet Gynecol 2012; 207: 276.e1-276.e10\n\n144 Tajik P, van der Ham DP, Zafarmand MH. et al. Using vaginal Group B Streptococcus colonisation in women with preterm premature rupture of membranes to guide the decision for immediate delivery: a secondary analysis of the PPROMEXIL trials. BJOG 2014; 121: 1263-1272 discussion 1273\n\n145 Quist-Nelson J, de Ruigh AA, Seidler AL. et al. Preterm Premature Rupture of Membranes Meta-analysis (PPROMM) Collaboration. Immediate Delivery Compared With Expectant Management in Late Preterm Prelabor Rupture of Membranes: An Individual Participant Data Meta-analysis. Obstet Gynecol 2018; 131: 269-279\n\n146 Brisch KH. Prävention durch prä- und postnatale Psychotherapie. In: Brisch K-H, Hellbrügge T. Hrsg. Die Anfänge der Eltern-Kind-Bindung. Schwangerschaft, Geburt und Psychotherapie. Stuttgart: Klett-Cotta; 2007: 271-303\n\n147 Wehkamp KH. Psychosoziale Ätiologie und psychosomatische Betreuung bei vorzeitigen Wehen. Arch Gynecol Obstet 1987; 242: 712-713\n\n148 Mahler G, Grab D, Kächele H, Kreienberg R, Zimmer I. Geeignete Bewältigung bei drohender Frühgeburt – Expertenrating. In: Rohde A, Riecher-Rössler A. Hrsg. Psychische Erkrankungen bei Frauen – Psychiatrie und Psychosomatik in der Gynäkologie. Regensburg: S. Roderer Verlag; 2001: 226-232\n\n149 Fisch S, Klapp C, Bergmann R. et al. Psychosoziales Frühwarnsystem Babylotse Plus – Untersuchung der diagnostischen Genauigkeit des Babylotse Plus Screeningbogens. Z Geburtshilfe Neonatol 2015; 219 - P201_214\n\n150 Frühgeborene: Für Familien. Online: https://www.fruehgeborene.de/fuer-familien last access: 28.04.2019\n\n151 Frühe Hilfen. Online: https://www.fruehehilfen.de last access: 28.04.2019\n\nCorrespondence/Korrespondenzadresse\n\nProf. Dr. med. Richard Berger\n\nMarienhaus Klinikum St. Elisabeth\n\nAkademisches Lehrkrankenhaus der Universitäten Mainz und Maastricht\n\nKlinik für Gynäkologie und Geburtshilfe\n\nFriedrich-Ebert-Straße 59\n\n56564 Neuwied\n\nGermany\n\nReferences/Literatur\n\n1 Fischer T, Mörtl M, Reif P. et al. Statement by the OEGGG with Review of the Literature on the Mode of Delivery of Premature Infants at the Limit of Viability. Geburtsh Frauenheilk 2018; 78: 1212-1216\n\n2 Gyamfi-Bannerman C, Thom EA, Blackwell SC. et al. NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374: 1311-1320\n\n3 SGGG. Lungenreifungsinduktion bei drohender Frühgeburt. Online: https://www.sggg.ch/fileadmin/user_upload/56_Lungenreifungsinduktion_bei_drohender_Fruehgeburt.pdf last access: 28.04.2019\n\n4 Swiss-Paediatrics. Perinatale Betreuung an der Grenze der Lebensfähigkeit zwischen 22 und 26 vollendeten Schwangerschaftswochen. Online: http://www.swiss-paediatrics.org/sites/default/files/paediatrica/vol23/n1/pdf/10-12_0.pdf last access: 28.04.2019\n\n5 SGGG. Expertenbrief Tokolyse. Online: https://www.sggg.ch/fileadmin/user_upload/Dokumente/3_Fachinformationen/1_Expertenbriefe/De/41_Tokolyse_2013.pdf last access: 28.04.2019\n\n6 Sosa CG, Althabe F, Belizán JM. et al. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2015; (03) CD003581\n\n7 Hobel CJ, Ross MG, Bemis RL. et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol 1994; 170: 54-62\n\n8 Elliott JP, Miller HS, Coleman S. et al. A randomized multicenter study to determine the efficacy of activity restriction for preterm labor management in patients testing negative for fetal fibronectin. J Perinatol 2005; 25: 626-630\n\n9 Bigelow CA, Factor SH, Miller M. et al. Pilot Randomized Controlled Trial to Evaluate the Impact of Bed Rest on Maternal and Fetal Outcomes in Women with Preterm Premature Rupture of the Membranes. Am J Perinatol 2016; 33: 356-363\n\n10 da Silva Lopes K, Takemoto Y, Ota E. et al. Bed rest with and without hospitalisation in multiple pregnancy for improving perinatal outcomes. Cochrane Database Syst Rev 2017; (03) CD012031\n\n11 Haas DM, Imperiale TF, Kirkpatrick PR. et al. Tocolytic therapy: A meta-analysis and decision analysis. Obstet Gynecol 2009; 113: 585-594\n\n12 Haas DM, Caldwell DM, Kirkpatrick P. et al. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345: e6226\n\n13 de Heus R, Mol BW, Erwich JJ. et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009; 338: b744\n\n14 Vogel JP, Oladapo OT, Manu A. et al. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health 2015; 3: e589-e590\n\n15 Crowther CA, Brown J, McKinlay CJ. et al. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2014; (08) CD001060\n\n16 [Anonymous] Practice Bulletin No. 171: Management of Preterm Labor. Obstet Gynecol 2016; 128: e155-e164\n\n17 Sentilhes L, Senat MV, Ancel PY. et al. Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol 2017; 210: 217-224\n\n18 Di Renzo GC, Cabero Roura L, Facchinetti F. et al. Preterm Labor and Birth Management: Recommendations from the European Association of Perinatal Medicine. J Matern Fetal Neonatal Med 2017; 30: 2011-2030\n\n19 Vogel JP, Nardin JM, Dowswell T. et al. Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database Syst Rev 2014; (07) CD006169\n\n20 Martinez de Tejada B, Karolinski A, Ocampo MC. et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG 2015; 122: 80-91\n\n21 Miyazaki C, Moreno Garcia R, Ota E. et al. Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis. Reprod Health 2016; 13: 4\n\n22 Dodd JM, Crowther CA, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev 2012; (12) CD003927\n\n23 Naik Gaunekar N, Raman P, Bain E. et al. Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (10) CD004071\n\n24 van Vliet E, Dijkema GH, Schuit E. et al. Nifedipine maintenance tocolysis and perinatal outcome: an individual participant data meta-analysis. BJOG 2016; 123: 1753-1760\n\n25 Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (05) CD000940\n\n26 Wood S, Rabi Y, Tang S. et al. Progesterone in women with arrested premature labor, a report of a randomised clinical trial and updated meta-analysis. BMC Pregnancy Childbirth 2017; 17: 258\n\n27 Pratcorona L, Goya M, Merced C. et al. Cervical pessary to reduce preterm birth < 34 weeks of gestation after an episode of preterm labor and a short cervix: a randomized controlled trial. Am J Obstet Gynecol 2018; 219: 99.e16\n\n28 Hermans FJR, Schuit E, Bekker MN. et al. Cervical Pessary After Arrested Preterm Labor: A Randomized Controlled Trial. Obstet Gynecol 2018; 132: 741-749\n\n29 King J, Flenady V. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev 2002; (04) CD000246\n\n30 Simcox R, Sin WT, Seed PT. et al. Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis. Aust N Z J Obstet Gynaecol 2007; 47: 368-377\n\n31 Roberts D, Brown J, Medley N. et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; (03) CD004454\n\n32 Deshmukh M, Patole S. Antenatal corticosteroids for neonates born before 25 Weeks-A systematic review and meta-analysis. PLoS One 2017; 12: e0176090\n\n33 Zephyrin LC, Hong KN, Wapner RJ. et al. Gestational age-specific risks vs. benefits of multicourse antenatal corticosteroids for preterm labor. Am J Obstet Gynecol 2013; 209: 330.e337\n\n34 Norman M, Piedvache A, Borch K. et al. Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results from the EPICE Cohort. JAMA Pediatr 2017; 171: 678-686\n\n35 Liebowitz M, Clyman RI. Antenatal Betamethasone: A Prolonged Time Interval from Administration to Delivery Is Associated with an Increased Incidence of Severe Intraventricular Hemorrhage in Infants Born before 28 Weeks Gestation. J Pediatr 2016; 177: 114-120.e1\n\n36 Norberg H, Kowalski J, Marsal K. et al. Timing of antenatal corticosteroid administration and survival in extremely preterm infants: a national population-based cohort study. BJOG 2017; 124: 1567-1574\n\n37 van Baaren GJ, Vis JY, Wilms FF. et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014; 123: 1185-1192\n\n38 Melchor JC, Khalil A, Wing D. et al. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52: 442-451\n\n39 Khandelwal M, Chang E, Hansen C. et al. Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial. Am J Obstet Gynecol 2012; 206: 201.e1-201.e11\n\n40 Stutchfield P, Whitaker R, Russell I. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331: 662\n\n41 Stutchfield PR, Whitaker R, Gliddon AE. et al. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed 2013; 98: F195-F200\n\n42 Ehsanipoor RM, Seligman NS, Saccone G. et al. Physical Examination-Indicated Cerclage. Obstet Gynecol 2015; 126: 125-135\n\n43 Miller ES, Grobman WA, Fonseca L. et al. Indomethacin and antibiotics in examination-indicated cerclage: a randomized controlled trial. Obstet Gynecol 2014; 123: 1311-1316\n\n44 Volpe J. Neurology of the Newborn. Philadelphia: W.B. Saunders Company; 1995\n\n45 Doyle LW, Crowther CA, Middleton P. et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (01) CD004661\n\n46 Crowther CA, Middleton PF, Voysey M. et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med 2017; 14: e1002398\n\n47 Backes CH, Rivera BK, Haque U. et al. Placental transfusion strategies in very preterm neonates: A systematic review and meta-analysis. Obstet Gynecol 2014; 124: 47-56\n\n48 Tarnow-Mordi W, Morris J, Kirby A. et al. Delayed versus Immediate Cord Clamping in Preterm Infants. N Engl J Med 2017; 377: 2445-2455\n\n49 Fogarty M, Osborn DA, Askie L. et al. Delayed vs. early umbilical cord clamping for preterm infants: a systematic review and meta-analysis. Am J Obstet Gynecol 2018; 218: 1-18\n\n50 Jonas HA, Khalid N, Schwartz SM. The relationship between Caesarean section and neonatal mortality in very-low-birthweight infants born in Washington State, USA. Paediatr Perinat Epidemiol 1999; 13: 170-189\n\n51 Lee HC, Gould JB. Survival rates and mode of delivery for vertex preterm neonates according to small- or appropriate-for-gestational-age status. Pediatrics 2006; 118: e1844\n\n52 Muhuri PK, Macdorman MF, Menacker F. Method of delivery and neonatal mortality among very low birth weight infants in the United States. Matern Child Health J 2006; 10: 47-53\n\n53 Malloy MH. Impact of cesarean section on neonatal mortality rates among very preterm infants in the United States, 2000–2003. Pediatrics 2008; 122: 285-292\n\n54 Jonas HA, Lumley JM. The effect of mode of delivery on neonatal mortality in very low birthweight infants born in Victoria, Australia: Caesarean section is associated with increased survival in breech-presenting, but not vertex-presenting, infants. Paediatr Perinat Epidemiol 1997; 11: 181-199\n\n55 Riskin A, Riskin-Mashiah S, Lusky A. et al. The relationship between delivery mode and mortality in very low birthweight singleton vertex-presenting infants. BJOG 2004; 111: 1365-1371\n\n56 Wylie BJ, Davidson LL, Batra M. et al. Method of delivery and neonatal outcome in very low-birthweight vertex-presenting fetuses. Am J Obstet Gynecol 2008; 198: 4\n\n57 Ghi T, Maroni E, Arcangeli T. et al. Mode of delivery in the preterm gestation and maternal and neonatal outcome. J Matern Fetal Neonatal Med 2010; 23: 1424-1428\n\n58 Durie DE, Sciscione AC, Hoffman MK. et al. Mode of delivery and outcomes in very low-birth-weight infants in the vertex presentation. Am J Perinatol 2011; 28: 195-200\n\n59 Reddy UM, Zhang J, Sun L. et al. Neonatal mortality by attempted route of delivery in early preterm birth. Am J Obstet Gynecol 2012; 207: 117.e1-117.e8\n\n60 Barzilay E, Gadot Y, Koren G. Safety of vaginal delivery in very low birthweight vertex singletons: a meta-analysis. J Matern Fetal Neonatal Med 2016; 29: 3724-3729\n\n61 Humberg A, Hartel C, Paul P. et al. Delivery mode and intraventricular hemorrhage risk in very-low-birth-weight infants: Observational data of the German Neonatal Network. Eur J Obstet Gynecol Reprod Biol 2017; 212: 144-149\n\n62 Holzer I, Lehner R, Ristl R. et al. Effect of delivery mode on neonatal outcome among preterm infants: an observational study. Wien Klin Wochenschr 2017; 129: 612-617\n\n63 Racusin DA, Antony KM, Haase J. et al. Mode of Delivery in Premature Neonates: Does It Matter?. AJP Rep 2016; 6: e251-e259\n\n64 Bergenhenegouwen L, Vlemmix F, Ensing S. et al. Preterm breech presentation: A comparison of intended vaginal and intended cesarean delivery. Obstet Gynecol 2015; 126: 1223-1230\n\n65 Landon MB, Hauth JC, Leveno KJ. et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 2004; 351: 2581-2589\n\n66 Landon MB, Lynch CD. Optimal timing and mode of delivery after cesarean with previous classical incision or myomectomy: a review of the data. Semin Perinatol 2011; 35: 257-261\n\n67 Aberg K, Norman M, Ekeus C. Preterm birth by vacuum extraction and neonatal outcome: A population-based cohort study. BMC Pregnancy Childbirth 2014; 14: 42\n\n68 Franz A, Härtel C, Herting E, für die Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI) (Federführung); Kehl S für die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG); Gille C für die Deutsche Gesellschaft für pädiatrische Infektiologie (DGPI); Doubek K für den Berufsverband der Frauenärzte BVF e. V.; Spellerberg B für die Deutsche Gesellschaft für Hygiene und Mikrobiologie (DGHM); Maier RF, Vetter K, für die Deutsche Gesellschaft für Perinatale Medizin (DGPM), Eglin K. für den Bundesverband „Das frühgeborene Kind“ e. V. (BVDfK). Sepsis bei Neugeborenen-frühe Form-durch Streptokokken der Gruppe B, Prophylaxe. Online: https://www.awmf.org/leitlinien/detail/ll/024-020.html last access: 03.12.2018\n\n69 Simon A, (Leiter der Arbeitsgruppe) Christoph J, Geffers C. et al. Empfehlung zur Prävention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1500 g. Online: https://www.rki.de/DE/Content/Infekt/Krankenhaushygiene/Kommission/Downloads/Neo_Rili.pdf?__blob=publicationFile last access: 28.04.2019\n\n70 Simon A. (federführender Autor) Ergänzende Empfehlung (2011) zur „Prävention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1.500 g“ (2007). Online: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2012/Ausgaben/02_12.pdf?__blob=publicationFile last access: 28.04.2019\n\n71 Christoph J, Dame C, Eckmanns T. et al. Praktische Umsetzung sowie krankenhaushygienische und infektionspräventive Konsequenzen des mikrobiellen Kolonisationsscreenings bei intensivmedizinisch behandelten Früh- und Neugeborenen. Online: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/42_13.pdf?__blob=publicationFile last access: 28.04.2019\n\n72 Richtlinie Qualitätssicherungs-Richtlinie Früh- und Reifgeborene, Stand: Inkrafttreten 01.01.2018 des Gemeinsamen Bundesausschusses über Maßnahmen zur Qualitätssicherung der Versorgung von Früh- und Reifgeborenen gemäß § 136 Absatz 1 Nummer 2 SGBV in Verbindung mit § 92 Abs. 1 Satz 2 Nr. 13 SGB V. Online: https://www.g-ba.de/downloads/62-492-1487/QFR-RL_2017-10-19_iK-2018-01-01.pdf last access: 28.04.2019\n\n73 Destatis. Todesursachen. Online: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Todesursachen.html last access: 28.04.2019\n\n74 Bundesverband „Das frühgeborene Kind“ e.V.. Leitsätze für Palliativversorgung und Trauerbegleitung in der Peri- und Neonatologie. Online: https://www.fruehgeborene.de/fuer-fachleute/palliativversorgung-und-trauerbegleitung last access: 28.04.2019\n\n75 Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung. Deutsches Ärzteblatt: Ausgabe A, Praxis-Ausgabe: niedergelassene Ärzte 2011; 108 (07) A346-A348 Online: https://www.bundesaerztekammer.de/fileadmin/user_upload/downloads/Sterbebegleitung_17022011.pdf last access: 28.04.2019\n\n76 IQTIG. Bundesauswertung zum Erfassungsjahr 2017 – Geburtshilfe Qualitätsindikatoren. Online: https://iqtig.org/downloads/auswertung/2017/16n1gebh/QSKH_16n1-GEBH_2017_BUAW_V02_2018-08-01.pdf last access: 28.04.2019\n\n77 AQUA-Institut. 16/1 – Geburtshilfe Qualitätsindikatoren. Online: https://sqg.de/downloads/Bundesauswertungen/2014/bu_Gesamt_16N1-GEBH_2014.pdf last access: 28.04.2019\n\n78 Dodd JM, Grivell RM, OBrien CM. et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev 2017; (10) CD012024\n\n79 Serra V, Perales A, Meseguer J. et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG 2013; 120: 50-57\n\n80 Fonseca EB, Celik E, Parra M. et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357: 462-469\n\n81 Cetingoz E, Cam C, Sakalli M. et al. Progesterone effects on preterm birth in high-risk pregnancies: A randomized placebo-controlled trial. Arch Gynecol Obstet 2011; 283: 423-429\n\n82 Brizot ML, Hernandez W, Liao AW. et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2015; 213: 82.e1-82.e9\n\n83 Elrefaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet 2016; 293: 61-67\n\n84 Rode L, Klein K, Nicolaides KH. et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011; 38: 272-280\n\n85 Romero R, Conde-Agudelo A, El-Refaie W. et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017; 49: 303-314\n\n86 Berghella V, Odibo AO, To MS. et al. Cerclage for short cervix on ultrasonography: Meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106: 181-189\n\n87 Rust OA, Atlas RO, Reed J. et al. Revisiting the short cervix detected by transvaginal ultrasound in the second trimester: why cerclage therapy may not help. Am J Obstet Gynecol 2001; 185: 1098-1105\n\n88 Berghella V, Odibo AO, Tolosa JE. Cerclage for prevention of preterm birth in women with a short cervix found on transvaginal ultrasound examination: a randomized trial. Am J Obstet Gynecol 2004; 191: 1311-1317\n\n89 Althuisius SM, Dekker GA, Hummel P. et al. Final results of the Cervical Incompetence Prevention Randomized Cerclage Trial (CIPRACT): therapeutic cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol 2001; 185: 1106-1112\n\n90 Saccone G, Rust O, Althuisius S. et al. Cerclage for short cervix in twin pregnancies: systematic review and meta-analysis of randomized trials using individual patient-level data. Acta Obstet Gynecol Scand 2015; 94: 352-358\n\n91 Liem S, Schuit E, Hegeman M. et al. Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label randomised controlled trial. Lancet 2013; 382: 1341-1349\n\n92 Goya M, de la Calle M, Pratcorona L. et al. PECEP-Twins Trial Group. Cervical pessary to prevent preterm birth in women with twin gestation and sonographic short cervix: A multicenter randomized controlled trial (PECEP-Twins). Am J Obstet Gynecol 2016; 214: 145-152\n\n93 Dang VQ, Nguyen LK, He YTN. et al. Cervical pessary versus vaginal progesterone for the prevention of preterm birth in women with a twin pregnancy and a cervix < 38 mm: A randomized controlled trial. Am J Obstet Gynecol 2018; 218: 603-604\n\n94 Nicolaides KH, Syngelaki A, Poon LC. et al. Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. Am J Obstet Gynecol 2016; 214: 3.e1-3.e9\n\n95 Berghella V, Dugoff L, Ludmir J. Prevention of preterm birth with pessary in twins (PoPPT): a randomized controlled trial. Ultrasound Obstet Gynecol 2017; 49: 567-572\n\n96 Carreras E. Cervical pessary for preventing birth in Twin pregnancies with maternal short cervix after an episode of threatened preterm labour: randomised control trial. Abstract, 17th World Congress in Fetal Medicine, Athen 2018.\n\n97 Rebarber A, Bender S, Silverstein M. et al. Outcomes of emergency or physical examination-indicated cerclage in twin pregnancies compared to singleton pregnancies. Eur J Obstet Gynecol Reprod Biol 2014; 173: 43-47\n\n98 Miller ES, Rajan PV, Grobman WA. Outcomes after physical examination-indicated cerclage in twin gestations. Am J Obstet Gynecol 2014; 211: 46.e1-46.e5\n\n99 Roman A, Rochelson B, Fox NS. et al. Efficacy of ultrasound-indicated cerclage in twin pregnancies. Am J Obstet Gynecol 2015; 212: 788.e1-788.e6\n\n100 Park JY, Cho SH, Jeon SJ. et al. Outcomes of physical examination-indicated cerclage in twin pregnancies with acute cervical insufficiency compared to singleton pregnancies. J Perinat Med 2018; 46: 845-852\n\n101 van der Heyden JL. Preterm prelabor rupture of membranes: different gestational ages, different problems [Thesis]. Maastricht: Maastricht University; 2014\n\n102 Mercer BM, Goldenberg RL, Moawad AH. et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181: 1216-1221\n\n103 Asrat T, Lewis DF, Garite TJ. et al. Rate of recurrence of preterm premature rupture of membranes in consecutive pregnancies. Am J Obstet Gynecol 1991; 165: 1111-1115\n\n104 Ramsauer B, Vidaeff AC, Hosli I. et al. The diagnosis of rupture of fetal membranes (ROM): a meta-analysis. J Perinat Med 2013; 41: 233-240\n\n105 Palacio M, Kuhnert M, Berger R. et al. Meta-analysis of studies on biochemical marker tests for the diagnosis of premature rupture of membranes: comparison of performance indexes. BMC Pregnancy Childbirth 2014; 14: 183\n\n106 Munson LA, Graham A, Koos BJ. et al. Is there a need for digital examination in patients with spontaneous rupture of the membranes?. Am J Obstet Gynecol 1985; 153: 562-563\n\n107 Alexander JM, Mercer BM, Miodovnik M. et al. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. Am J Obstet Gynecol 2000; 183: 1003-1007\n\n108 Mercer BM, Miodovnik M, Thurnau GR. et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997; 278: 989-995\n\n109 Melamed N, Hadar E, Ben-Haroush A. et al. Factors affecting the duration of the latency period in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2009; 22: 1051-10"
    }
}